|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further support has been garnered with the results of CIRT (Cardiovascular Inflammation Reduction Trial), which showed the inability of low-dose methotrexate to reduce IL-1ß, IL-6, or high-sensitivity CRP (hsCRP) in addition to MACE among patients with prior MI or multivessel coronary artery disease (CAD) but with normal hsCRP levels.
|
31469975 |
2020 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of IL-6, TNF-α, and inflammatory related molecules ICAM-1, VCAM-1, MMP-2 and -9, nuclear NF-kB, and iNOS, were elevated in MI-V.
|
30642049 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both adrenergic stimulation and high levels of interleukin-6 (IL-6) indicate an unfavorable outcome in patients with myocardial infarction or heart failure.
|
31749886 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Another 20 mice with IL-6 gene knockout were enrolled into the MI + IL-6 KO group.
|
31364133 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that serum concentrations of interleukin-6 (IL6) and lipoprotein-associated phospholipase A2 (LpPLA2) were inversely associated with long-term functional decline independently of vascular risk factors, stroke and myocardial infarction (MI) occurring during follow-up.
|
30934019 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MI group produced a significant increase in myocardial infarct size, serum cardiac biomarkers (LDH and CK-MB), proinflammatory cytokines (TNF-α and IL-6), and MDA levels, and a significant decrease in SOD level compared with the sham group.
|
31280453 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that CDH11-expressing cells contribute to inflammation-driven fibrotic remodeling after MI and that targeting CDH11 with a blocking antibody improves outcomes by altering recruitment of bone marrow-derived cells, limiting the macrophage-induced expression of IL-6 by fibroblasts and promoting vascularization.
|
31534054 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
CCNP was more efficient than CC in limiting the increase in inflammatory cytokine levels (such as TNF-<i>α</i>, IL-6, IL-1<i>α</i>, IL-1<i>β</i>, MCP-1, and RANTES) after MI.
|
31205590 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Posttraumatic stress disorder is associated with enhanced interleukin-6 response to mental stress in subjects with a recent myocardial infarction.
|
30172946 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with control group, the levels of heart rate, left ventricular end-diastolic pressure, TNF-α, and IL-6 were increased in each group of rats with MI (all p < 0.05), while the levels of systolic blood pressure, diastolic blood pressure, mean arterial pressure, left ventricular systolic pressure, and IL-10 were significantly decreased (all p < 0.05).
|
31218464 |
2019 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
The level of systemic inflammation will be evaluated based on the serum biomarker levels (hs-CRP, matrix metalloproteinases, interleukin-6) in the acute phase of the myocardial infarction (MI) and at 1 month.
|
31027064 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression level of Angptl 2 and IL-6 in the myocardial infarction group was significantly higher than that in the control group P<0.001.
|
30988729 |
2019 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of the pro-inflammatory cytokines interleukin-6 and interleukin-1β were upregulated in hearts of vehicle treated animals compared to mice without MI.
|
29169754 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we investigated products of complement activation, C3d and soluble C5b9 (sC5b9), as potential biomarkers for myocardial injury and inflammation, as well as serum cytokines (IL-6 and TNF-alpha), alpha-1-acid glycoprotein (AGP), and classical markers of myocardial necrosis (creatine kinase, creatine kinase-MB isoform, myoglobin and troponin-I) in a longitudinal study of patients with AMI (from admission, 6 h and 12 h post admission, and at discharge from hospital).
|
29908956 |
2018 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of inflammatory genes such as IL-1β and IL-6 was upregulated in the non-infarcted zone of MPGKO mice after MI.
|
29800789 |
2018 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction.
|
28250574 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) has been found to be a predictor of heart attack.
|
28233119 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequently they were tested for IL-6 secretion inhibition in RAW 264.7 macrophages and for cardiac function protection against adverse remodeling after MI in C57BL/6J mice.
|
28065862 |
2017 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum interleukin-6 levels in patients with AMI were significantly higher than nonischemic controls (0.4 ± 0.2 ng/mL versus 0.2 ± 0.07 ng/mL, respectively, P = 0.03).
|
27555111 |
2017 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, S+MI group, but not S alone, showed a significant increase in the expression of connective tissue growth factor (CTGF) and fibrotic proteins fibronectin (FN) and <i>α</i>-smooth muscle actin (SMA), in comparison to controls, in addition to a significant increase in mRNA levels of IL-6 and TNF-<i>α</i> inflammatory markers.
|
29177025 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.
|
28432157 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 concentration was assessed at baseline in 4939 subjects in SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients ≤30 days from ACS.
|
29066436 |
2017 |
|
Myocardial Infarction
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6, an upstream inflammatory marker, was independently associated with the risk of major adverse cardiovascular events, cardiovascular and all-cause mortality, myocardial infarction, heart failure, and cancer mortality in patients with stable coronary heart disease.
|
29066452 |
2017 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
AMI rats showed increased levels of IL-6 and TNF-<i>α</i>.
|
28373886 |
2017 |
|
Myocardial Infarction
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured serum activated protein C and interleukin-6 levels in 43 patients with cardiogenic shock following acute myocardial infarction and in 15 control patients with uncomplicated myocardial infarction at days 0-5 and 7 after the onset of shock/myocardial infarction.
|
26936869 |
2017 |